FMRFamide-like neuropeptides (PubMed:16377032, PubMed:28128367). Stimulates serotonin-induced fat loss by binding to and activating the npr-22 receptor which leads to induction of the atgl-1 lipase and subsequent fat loss (PubMed:33078707). Together with atfs-1, negatively regulates the expression of the transcription regulator hlh-11, to promote expression of atgl-1, and thus atgl-1-dependent fat oxidation in response to mitochondrial stress (PubMed:33078707). TPMQRSSMVRF-amide: Acts as a ligand for the npr-22 receptor in vitro. SPMQRSSMVRF-amide: Acts as a ligand for the npr-22 receptor in vitro. Acts as a ligand for the npr-22 receptor in vitro. Acts as a ligand for the npr-22 receptor in vitro. Secreted from the ASI sensory neurons in response to serotonin or octopamine. Expressed in the ASI sensory neurons, the ALA interneuron and the AVG interneuron from where secretion occurs. Expression in the ASI neurons is necessary and sufficient to maintain serotonin-induced fat loss. Expressed in eggs, all larval stages and in adult (PubMed:9685599). Expressed in the ALA neuron in L4 stage larvae (PubMed:27546573). Retention of a significantly greater proportion of body fat compared to wild-type following treatment with serotonin, almost complete suppression of the transcriptional induction of the atgl-1 lipase, reduced egg-laying and suppression of octopamine-induced fat loss. No effect on serotonin-induced food intake, reproduction or the enhanced slowing response which is a satiety-like locomotor response to food availability. Belongs to the FARP (FMRFamide related peptide) family.